HIV
Conditions
Interventions
LA group:NA
SOC group:NA
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years at the time of signing the informed consent form 2. Presence of proven HIV-1 infection 3. prior to study participation and irrespective of study participation status, initiating CAB+RPVLA therapy or continuing daily oral ART therapy, as indicated. Participants may be enrolled in the following treatment groups: (1) LA group: start CAB+RPV LA therapy according to indication (start injections directly and receive first injection at the study centre on the last day of any other antiretroviral therapy); (2) Control group: continue to receive the current standard oral antiretroviral regimen (first-line oral regimen in accordance with the recommendations of the Chinese HIV/AIDS Clinical Guidelines [2024 Edition]) and be stable on treatment for >= 3 months and virologically suppressed (HIV RNA = 6 months. 4. Understand and cooperate in completing the questionnaire 5. Sign the informed consent form for participation in the study.
Exclusion criteria
Exclusion criteria: 1. LA group: any contraindication to CAB LA, RPV LA (known resistance and/or hypersensitivity to CAB or RPV; loss of virological response due to co-administration of drugs that may significantly reduce CAB and/or RPV plasma concentrations); control group: contraindications to current use of conventional oral ART medications (e.g., drug allergy, drug resistance, severe hepatic or renal insufficiency, etc.). Control group: contraindications to the current use of conventional oral ART drugs (e.g. drug allergy, drug resistance, severe hepatic or renal insufficiency, inability to tolerate oral drugs) 2. LA group: history of CAB+RPV LA treatment before enrolment; control group: oral ART regimen has been adjusted within 3 months before enrolment or is planned to be adjusted within 3 months after enrolment. 3. Currently participating in any pharmacological or non-pharmacological interventional study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIV viral load; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD4 cell; | — |
Countries
China
Contacts
Public ContactLijun Sun
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed